Market Intelligence Signals
Thread 5 — Oncology US market · disruption & risk signals with feature explainability
199 drug × indication signals
65 high disruption signals
Updated 2026-08-30
What this page is — and is not
This week's analysis
Model Review Agent · 2026-08-30
Overview

This week's models cover 199 drug×indication pairs across 85 drugs and 16 indications, with CV AUC of 0.88 for the approval model — but this should be read with caution: labels were constructed in-sample and the model is effectively driven by a single feature (regulatory momentum). Four of nine features remain 100% null, including NIH funding momentum, publication velocity, CMS spend trajectory, and patent cliff proximity — limiting all models to 56% feature completeness. The disruption risk score is a useful relative index but is not a validated forecast. Revenue trajectory should be treated as directional only given the 2-year CMS data lag. Notable this week: AVASTIN shows very low approval probability (0.04) but high disruption (0.87) driven by an unusually high shortage_risk_score of 24, and 31 predictions saturate at approval probability = 1.0, indicating the model cannot differentiate among already-approved drugs.

Model quality
approval model informativeTrue
approval cv auc0.8763
approval label balance okFalse
approval dominant featureregulatory_momentum_approval_count
approval quality noteCV AUC 0.88 is nominally strong but the label split is 77%/23% (imbalanced) and labels were constructed in-sample from the KG — not a held-out external dataset. The model is effectively a single-feature threshold on regulatory_momentum_approval_count, which appears in the top-3 drivers for all 199 predictions. Treat scores as directional signals, not calibrated probabilities.
disruption model informativeTrue
disruption quality noteOnly two features have non-zero permutation importance: regulatory_momentum_approval_count (0.262) and shortage_risk_score (0.224). pipeline_density_trial_count is negligible (0.0002) and policy_risk_score and trial_anomaly_rate are zero. The disruption score is effectively a two-feature index of regulatory activity and supply fragility — not a validated disruption forecast.
revenue model noteRevenue trajectory index uses CMS Medicare Part D data with a ~2yr publication lag. All 199 rows have cms_spend_trajectory_usd_per_yr as null, so the revenue model is operating without its primary signal — treat all revenue indices as directional only and very weakly informed.
Notable signals this week
AVASTIN Renal Cell Carcinoma approval probability 3.6% Lowest approval probability in the dataset despite being an established drug — driven by reg_mom=1 (only one approval counted) versus the high shortage_risk_score=24 which inflates disruption to 0.87. The model conflates originator bevacizumab (single approval) with biosimilars that have their own approval counts, creating artificially low scores for the originator.
BORTEZOMIB Multiple Myeloma approval probability 100.0% Saturates at 1.0 with disruption also at 1.0 — driven by reg_mom=10 (ten approvals counted) and shortage=3. Plausible given bortezomib's long market presence, but the model provides no granularity among high-approval drugs. Also flagged as EOI-002 by the Edge Discovery agent.
OPDIVO QVANTIG Gastric Cancer approval probability 100.0% Near-certain approval probability driven by reg_mom=5. Matches EOI-003 signal (Opdivo gastric approval this week). However, the originator 'Opdivo' node has reg_mom=0 and scores only 0.414 — a label normalization gap where the biologic and its subcutaneous formulation are treated as separate drugs.
KEYTRUDA QLEX Bladder Cancer disruption risk score 98.3% High disruption score driven by reg_mom=2 and shortage=1. Matches EOI-004 signal (Keytruda bladder approval this week). The originator 'Keytruda' node scores only 0.421 approval and 0.010 disruption — the same label normalization gap as Opdivo.
VENCLEXTA Acute Myeloid Leukemia approval probability 95.9% High approval probability driven by reg_mom=2. Matches EOI-005 signal (Venclexta AML approval). The lowercase 'Venclexta' node scores 0.409 — another instance of the label normalization gap where the same drug appears as two separate nodes.
Feature improvement proposals (3)
drug label canonicalization low

The same drug appears as multiple nodes with different regulatory_momentum values (e.g. 'Opdivo' reg_mom=0 vs 'OPDIVO QVANTIG' reg_mom=5; 'Keytruda' reg_mom=0 vs 'KEYTRUDA QLEX' reg_mom=2; 'Venclexta' reg_mom=0 vs 'VENCLEXTA' reg_mom=2). This causes the model to assign dramatically different scores to the same drug. Fixing this is a KG normalization task, not a new data source — collapse originator and biologic formulation variants to a shared regulatory_momentum count.

nih funding momentum usd per yr medium

Currently null for all 199 rows (100%). NIH Reporter v2 API provides grant award data by condition/indication. Tier 2 commit log shows 10 proposals were committed this week to fill this and publication_velocity_cagr — these imputed values should be loaded into the feature matrix for the next cycle. See: https://api.reporter.nih.gov/

patent cliff proximity yrs medium

Currently null for all 199 rows (100%). FDA Orange Book downloadable data files provide patent expiry dates at https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files. Adding this would enable the model to distinguish drugs near patent expiry (higher competitive entry risk) from those with prolonged exclusivity — a signal currently entirely missing from both approval and disruption models.

199
Drug × indication signals
65
High disruption (≥60%)
199
Training rows (in-sample)
Yes
Disruption RF trained
Model details & data freshness
Data freshness by vertical
VerticalSourceCadence
Academic research PubMed · NIH Reporter weekly
Drug discovery ChEMBL · Open Targets weekly
Trials Thread 2 cross-ref daily
FDA regulatory openFDA Drugs@FDA weekly
Sales (CMS) CMS Part D 2yr lag — amber always
Manufacturing openFDA enforcement weekly
Distribution HRSA 340B weekly
Government policy Fed Register · Congress weekly
Model metadata
Approval rank (relative — not calibrated)
LogisticRegression(C=1.0, L2)
Label = 1 if drug has any approval post-2018, 0 otherwise. In-sample split — not an external held-out dataset. CV AUC is indicative only.
Disruption risk
RandomForestClassifier(n_estimators=50, max_depth=4)
Labels constructed from observable KG signals (shortage + competitive entry). No validated ground truth.
Revenue trajectory index
Ridge(alpha=1.0)
CMS Part D data has 2yr lag. Treat output as directional index only.
Market entry timing
Empirical approval year distribution per indication
Distribution of approval years, not trial duration. Trial start dates not yet in KG.
Filter:
Signal table — sorted by disruption risk

Click any row to expand feature contributions. Hover evidence column header for tooltip. — in raw features = null (score reliability reduced).

Drug ↕ Indication ↕ Disruption risk ↕ Appr. rank (rel.) ⓘ ↕ Revenue index ↕ Approval yr (median) ↕ Data completeness ⓘ ↕
AKEEGA
ABIRATERONE ACETATE
 Prostate Cancer 97.6% 100.0%
100.0–100.0%
 10.96 2022 (n=34) 56% ▸
AKEEGA
ABIRATERONE ACETATE
 Ovarian Cancer 93.8% 100.0%
100.0–100.0%
 10.96 2021 (n=40) 56% ▸
LENALIDOMIDE
 Multiple Myeloma 96.8% 100.0%
100.0–100.0%
 9.96 2023 (n=30) 56% ▸
LENALIDOMIDE
 Diffuse Large B-Cell Lymphoma 94.2% 100.0%
100.0–100.0%
 9.96 2025 (n=16) 56% ▸
LENALIDOMIDE
 Chronic Lymphocytic Leukemia 94.5% 100.0%
100.0–100.0%
 9.96 2024 (n=22) 56% ▸
BORTEZOMIB
 Multiple Myeloma 100.0% 100.0%
100.0–100.0%
 9.96 2023 (n=30) 56% ▸
ENZALUTAMIDE
 Prostate Cancer 97.6% 100.0%
100.0–100.0%
 5.98 2022 (n=34) 56% ▸
CABAZITAXEL
 Prostate Cancer 97.6% 100.0%
100.0–100.0%
 6.98 2022 (n=34) 56% ▸
DOCETAXEL
 Non-Small Cell Lung Cancer 91.2% 100.0%
100.0–100.0%
 9.96 2020 (n=48) 56% ▸
DOCETAXEL
 Gastric Cancer 94.9% 100.0%
100.0–100.0%
 9.96 2022 (n=69) 56% ▸
DOCETAXEL
 Prostate Cancer 97.6% 100.0%
100.0–100.0%
 9.96 2022 (n=34) 56% ▸
DOCETAXEL
 Head and Neck Cancer 96.8% 100.0%
100.0–100.0%
 9.96 2024 (n=26) 56% ▸
DOCETAXEL
 Breast Cancer 93.1% 100.0%
100.0–100.0%
 9.96 2023 (n=65) 56% ▸
PACLITAXEL
 Non-Small Cell Lung Cancer 91.2% 100.0%
100.0–100.0%
 6.98 2020 (n=48) 56% ▸
PACLITAXEL
 Ovarian Cancer 93.8% 100.0%
100.0–100.0%
 6.98 2021 (n=40) 56% ▸
PACLITAXEL
 Breast Cancer 93.1% 100.0%
100.0–100.0%
 6.97 2023 (n=65) 56% ▸
PACLITAXEL
 Gastric Cancer 94.9% 100.0%
100.0–100.0%
 6.98 2022 (n=69) 56% ▸
IRINOTECAN HYDROCHLORIDE
 Colorectal Cancer 95.0% 100.0%
100.0–100.0%
 7.97 2022 (n=52) 56% ▸
OXALIPLATIN
 Gastric Cancer 94.9% 100.0%
100.0–100.0%
 8.97 2022 (n=69) 56% ▸
OXALIPLATIN
 Colorectal Cancer 95.0% 100.0%
100.0–100.0%
 8.97 2022 (n=52) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Non-Small Cell Lung Cancer 91.2% 100.0%
100.0–100.0%
 9.96 2020 (n=48) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Ovarian Cancer 93.8% 100.0%
100.0–100.0%
 9.96 2021 (n=40) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Bladder Cancer 96.8% 100.0%
100.0–100.0%
 9.96 2020 (n=15) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Pancreatic Cancer 97.6% 100.0%
100.0–100.0%
 9.96 2020 (n=10) 56% ▸
TOLAK
FLUOROURACIL
 Gastric Cancer 94.9% 100.0%
100.0–100.0%
 7.97 2022 (n=69) 56% ▸
TOLAK
FLUOROURACIL
 Colorectal Cancer 95.0% 100.0%
100.0–100.0%
 7.97 2022 (n=52) 56% ▸
TOLAK
FLUOROURACIL
 Head and Neck Cancer 96.8% 100.0%
100.0–100.0%
 7.97 2024 (n=26) 56% ▸
TOLAK
FLUOROURACIL
 Breast Cancer 93.1% 100.0%
100.0–100.0%
 7.97 2023 (n=65) 56% ▸
CAPECITABINE
 Gastric Cancer 94.9% 100.0%
100.0–100.0%
 9.96 2022 (n=69) 56% ▸
CAPECITABINE
 Colorectal Cancer 95.0% 100.0%
100.0–100.0%
 9.96 2022 (n=52) 56% ▸
CAPECITABINE
 Breast Cancer 93.1% 100.0%
100.0–100.0%
 9.96 2023 (n=65) 56% ▸
CARFILZOMIB
 Multiple Myeloma 100.0% 100.0%
100.0–100.0%
 5.98 2023 (n=30) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Hepatocellular Carcinoma 100.0% 100.0%
100.0–100.0%
 4.99 2022 (n=15) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Non-Small Cell Lung Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2020 (n=48) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Gastric Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2022 (n=69) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Melanoma 98.7% 100.0%
100.0–100.0%
 4.99 2024 (n=8) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Renal Cell Carcinoma 99.2% 100.0%
100.0–100.0%
 4.99 2022 (n=14) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Colorectal Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2022 (n=52) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Head and Neck Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2024 (n=26) 56% ▸
IMBRUVICA
IBRUTINIB
 Chronic Lymphocytic Leukemia 68.5% 99.9%
99.8–99.9%
 3.99 2024 (n=22) 56% ▸
IBRANCE
PALBOCICLIB
 Breast Cancer 3.4% 97.1%
95.8–97.9%
 2.00 2023 (n=65) 56% ▸
VERZENIO
ABEMACICLIB
 Breast Cancer 3.4% 97.1%
95.8–97.9%
 2.00 2023 (n=65) 56% ▸
LYNPARZA
OLAPARIB
 Breast Cancer 3.4% 97.1%
95.9–97.9%
 2.00 2023 (n=65) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Breast Cancer 82.3% 96.5%
94.8–97.5%
 2.00 2023 (n=65) 56% ▸
LYNPARZA
OLAPARIB
 Ovarian Cancer 17.8% 95.9%
94.1–97.1%
 2.00 2021 (n=40) 56% ▸
ZEJULA
NIRAPARIB TOSYLATE
 Ovarian Cancer 17.8% 95.9%
94.1–97.2%
 2.00 2021 (n=40) 56% ▸
VENCLEXTA
VENETOCLAX
 Acute Myeloid Leukemia 15.6% 95.9%
94.4–97.3%
 2.00 2026 (n=2) 56% ▸
VENCLEXTA
VENETOCLAX
 Chronic Lymphocytic Leukemia 14.6% 95.7%
94.0–97.0%
 2.00 2024 (n=22) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Non-Small Cell Lung Cancer 96.9% 95.6%
93.9–97.0%
 2.00 2020 (n=48) 56% ▸
TECENTRIQ
ATEZOLIZUMAB
 Non-Small Cell Lung Cancer 96.9% 95.6%
94.1–96.8%
 2.00 2020 (n=48) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Colorectal Cancer 98.3% 95.4%
93.5–96.7%
 2.00 2022 (n=52) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Gastric Cancer 98.3% 95.3%
93.5–96.8%
 2.00 2022 (n=69) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Bladder Cancer 98.3% 95.3%
93.6–96.7%
 2.00 2020 (n=15) 56% ▸
TECENTRIQ
ATEZOLIZUMAB
 Bladder Cancer 98.3% 95.3%
93.3–96.7%
 2.00 2020 (n=15) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Head and Neck Cancer 98.0% 95.2%
93.3–96.6%
 2.00 2024 (n=26) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Hepatocellular Carcinoma 98.0% 95.2%
93.4–96.6%
 2.00 2022 (n=15) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Melanoma 94.6% 95.1%
93.3–96.7%
 2.00 2024 (n=8) 56% ▸
RITUXAN HYCELA
RITUXIMAB
 Diffuse Large B-Cell Lymphoma 92.3% 94.9%
92.7–96.3%
 2.00 2025 (n=16) 56% ▸
RITUXAN HYCELA
RITUXIMAB
 Chronic Lymphocytic Leukemia 92.3% 94.8%
93.1–96.3%
 2.00 2024 (n=22) 56% ▸
HERCESSI
TRASTUZUMAB-STRF
 Breast Cancer 2.5% 85.1%
80.5–89.2%
 1.00 2023 (n=65) 56% ▸
KANJINTI
TRASTUZUMAB-ANNS
 Breast Cancer 2.5% 85.1%
79.6–89.2%
 1.00 2023 (n=65) 56% ▸
OGIVRI
TRASTUZUMAB-DKST
 Breast Cancer 2.5% 85.1%
79.9–89.2%
 1.00 2023 (n=65) 56% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Breast Cancer 2.5% 85.1%
79.3–89.3%
 1.00 2023 (n=65) 56% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Breast Cancer 2.5% 85.1%
80.0–88.8%
 1.00 2023 (n=65) 56% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Breast Cancer 2.5% 85.1%
79.2–89.7%
 1.00 2023 (n=65) 56% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Breast Cancer 2.5% 85.1%
79.9–89.1%
 1.00 2023 (n=65) 56% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Breast Cancer 2.5% 85.1%
79.5–88.6%
 1.00 2023 (n=65) 56% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Breast Cancer 2.5% 85.1%
79.9–89.4%
 1.00 2023 (n=65) 56% ▸
POHERDY
PERTUZUMAB-DPZB
 Breast Cancer 2.5% 85.1%
80.6–89.0%
 1.00 2023 (n=65) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Breast Cancer 2.5% 85.1%
80.0–89.0%
 1.00 2023 (n=65) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Breast Cancer 2.5% 85.1%
79.2–89.2%
 1.00 2023 (n=65) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Breast Cancer 2.5% 85.1%
79.7–89.0%
 1.00 2023 (n=65) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Breast Cancer 2.5% 85.1%
80.4–89.0%
 1.00 2023 (n=65) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Breast Cancer 2.5% 85.1%
80.3–89.1%
 1.00 2023 (n=65) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Breast Cancer 2.5% 85.1%
81.0–88.9%
 1.00 2023 (n=65) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Breast Cancer 2.5% 85.1%
80.2–89.2%
 1.00 2023 (n=65) 56% ▸
KISQALI
RIBOCICLIB SUCCINATE
 Breast Cancer 2.5% 85.1%
80.8–89.4%
 1.00 2023 (n=65) 56% ▸
KISQALI FEMARA CO-PACK (COPACKAGED)
LETROZOLE
 Breast Cancer 2.5% 85.1%
80.6–88.7%
 1.00 2023 (n=65) 56% ▸
PERJETA
PERTUZUMAB
 Breast Cancer 81.8% 82.5%
75.8–87.4%
 1.00 2023 (n=65) 56% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Non-Small Cell Lung Cancer 3.7% 81.9%
75.6–86.2%
 1.01 2020 (n=48) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Non-Small Cell Lung Cancer 3.7% 81.9%
76.2–87.2%
 1.01 2020 (n=48) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Non-Small Cell Lung Cancer 3.7% 81.9%
76.7–86.2%
 1.01 2020 (n=48) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Non-Small Cell Lung Cancer 3.7% 81.9%
76.4–87.2%
 1.01 2020 (n=48) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Non-Small Cell Lung Cancer 3.7% 81.9%
76.1–86.0%
 1.01 2020 (n=48) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Non-Small Cell Lung Cancer 3.7% 81.9%
75.6–87.0%
 1.01 2020 (n=48) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Non-Small Cell Lung Cancer 3.7% 81.9%
75.9–86.4%
 1.01 2020 (n=48) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Non-Small Cell Lung Cancer 3.7% 81.9%
76.5–86.5%
 1.01 2020 (n=48) 56% ▸
TAGRISSO
OSIMERTINIB MESYLATE
 Non-Small Cell Lung Cancer 3.7% 81.9%
76.2–86.5%
 1.01 2020 (n=48) 56% ▸
ALECENSA
ALECTINIB HYDROCHLORIDE
 Non-Small Cell Lung Cancer 3.7% 81.9%
76.1–87.0%
 1.01 2020 (n=48) 56% ▸
YERVOY
IPILIMUMAB
 Colorectal Cancer 2.3% 81.3%
74.6–85.8%
 1.01 2022 (n=52) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Colorectal Cancer 2.3% 81.3%
75.7–86.4%
 1.01 2022 (n=52) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Colorectal Cancer 2.3% 81.3%
74.8–85.8%
 1.01 2022 (n=52) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Colorectal Cancer 2.3% 81.3%
74.9–86.5%
 1.01 2022 (n=52) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Colorectal Cancer 2.3% 81.3%
73.8–85.8%
 1.01 2022 (n=52) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Colorectal Cancer 2.3% 81.3%
75.2–85.4%
 1.01 2022 (n=52) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Colorectal Cancer 2.3% 81.3%
74.6–85.9%
 1.01 2022 (n=52) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Colorectal Cancer 2.3% 81.3%
75.5–85.9%
 1.01 2022 (n=52) 56% ▸
HERCESSI
TRASTUZUMAB-STRF
 Gastric Cancer 2.2% 81.0%
75.4–86.0%
 1.01 2022 (n=69) 56% ▸
KANJINTI
TRASTUZUMAB-ANNS
 Gastric Cancer 2.2% 81.0%
74.7–86.2%
 1.01 2022 (n=69) 56% ▸
OGIVRI
TRASTUZUMAB-DKST
 Gastric Cancer 2.2% 81.0%
75.6–85.7%
 1.01 2022 (n=69) 56% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Gastric Cancer 2.2% 81.0%
74.6–84.9%
 1.01 2022 (n=69) 56% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Gastric Cancer 2.2% 81.0%
74.5–86.0%
 1.01 2022 (n=69) 56% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Gastric Cancer 2.2% 81.0%
75.4–86.1%
 1.01 2022 (n=69) 56% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Gastric Cancer 2.2% 81.0%
75.2–85.9%
 1.01 2022 (n=69) 56% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Gastric Cancer 2.2% 81.0%
74.4–85.6%
 1.01 2022 (n=69) 56% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Gastric Cancer 2.2% 81.0%
75.1–85.7%
 1.01 2022 (n=69) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Gastric Cancer 2.2% 81.0%
73.8–85.7%
 1.01 2022 (n=69) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Gastric Cancer 2.2% 81.0%
73.1–85.5%
 1.01 2022 (n=69) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Gastric Cancer 2.2% 81.0%
75.7–86.0%
 1.01 2022 (n=69) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Gastric Cancer 2.2% 81.0%
73.7–85.3%
 1.01 2022 (n=69) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Gastric Cancer 2.2% 81.0%
75.3–85.7%
 1.01 2022 (n=69) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Gastric Cancer 2.2% 81.0%
74.8–85.9%
 1.01 2022 (n=69) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Gastric Cancer 2.2% 81.0%
74.0–85.3%
 1.01 2022 (n=69) 56% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Bladder Cancer 1.7% 80.9%
74.1–85.9%
 1.01 2020 (n=15) 56% ▸
DARZALEX
DARATUMUMAB
 Multiple Myeloma 1.7% 80.8%
75.6–85.0%
 1.01 2023 (n=30) 56% ▸
DARZALEX FASPRO
DARATUMUMAB AND HYALURONIDASE-FIHJ
 Multiple Myeloma 1.7% 80.8%
73.9–85.7%
 1.01 2023 (n=30) 56% ▸
NINLARO
IXAZOMIB CITRATE
 Multiple Myeloma 1.7% 80.8%
74.4–85.3%
 1.01 2023 (n=30) 56% ▸
EMPLICITI
ELOTUZUMAB
 Multiple Myeloma 1.7% 80.8%
75.2–85.5%
 1.01 2023 (n=30) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Hepatocellular Carcinoma 2.6% 80.4%
74.9–85.1%
 1.01 2022 (n=15) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Hepatocellular Carcinoma 2.6% 80.4%
73.8–85.9%
 1.01 2022 (n=15) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Hepatocellular Carcinoma 2.6% 80.4%
74.4–86.2%
 1.01 2022 (n=15) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Hepatocellular Carcinoma 2.6% 80.4%
74.9–85.3%
 1.01 2022 (n=15) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Hepatocellular Carcinoma 2.6% 80.4%
74.0–85.8%
 1.01 2022 (n=15) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Hepatocellular Carcinoma 2.6% 80.4%
73.6–85.0%
 1.01 2022 (n=15) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Hepatocellular Carcinoma 2.6% 80.4%
73.5–85.8%
 1.01 2022 (n=15) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Ovarian Cancer 3.2% 80.2%
74.1–85.5%
 1.01 2021 (n=40) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Ovarian Cancer 3.2% 80.2%
74.6–84.9%
 1.01 2021 (n=40) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Ovarian Cancer 3.2% 80.2%
75.2–85.3%
 1.01 2021 (n=40) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Ovarian Cancer 3.2% 80.2%
74.0–85.3%
 1.01 2021 (n=40) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Ovarian Cancer 3.2% 80.2%
73.8–85.3%
 1.01 2021 (n=40) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Ovarian Cancer 3.2% 80.2%
73.4–84.9%
 1.01 2021 (n=40) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Ovarian Cancer 3.2% 80.2%
73.5–85.3%
 1.01 2021 (n=40) 56% ▸
YERVOY
IPILIMUMAB
 Melanoma 1.1% 80.1%
74.0–85.2%
 1.01 2024 (n=8) 56% ▸
YERVOY
IPILIMUMAB
 Renal Cell Carcinoma 1.4% 79.6%
73.3–85.5%
 1.01 2022 (n=14) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Renal Cell Carcinoma 1.4% 79.6%
73.5–84.3%
 1.01 2022 (n=14) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Renal Cell Carcinoma 1.4% 79.6%
72.9–84.3%
 1.01 2022 (n=14) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Renal Cell Carcinoma 1.4% 79.6%
72.8–86.0%
 1.01 2022 (n=14) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Renal Cell Carcinoma 1.4% 79.6%
73.5–84.7%
 1.01 2022 (n=14) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Renal Cell Carcinoma 1.4% 79.6%
72.5–85.6%
 1.01 2022 (n=14) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Renal Cell Carcinoma 1.4% 79.6%
74.3–85.2%
 1.01 2022 (n=14) 56% ▸
LYTENAVA
BEVACIZUMAB-VIKG
 Renal Cell Carcinoma 1.4% 79.6%
73.2–84.5%
 1.01 2022 (n=14) 56% ▸
ZIMRIXBY
RITUXIMAB-CDXX
 Diffuse Large B-Cell Lymphoma 1.0% 79.4%
72.3–84.7%
 1.01 2025 (n=16) 56% ▸
TRUXIMA
RITUXIMAB-ABBS
 Diffuse Large B-Cell Lymphoma 1.0% 79.4%
73.0–84.1%
 1.01 2025 (n=16) 56% ▸
RUXIENCE
RITUXIMAB-PVVR
 Diffuse Large B-Cell Lymphoma 1.0% 79.4%
73.3–85.4%
 1.01 2025 (n=16) 56% ▸
RIABNI
RITUXIMAB-ARRX
 Diffuse Large B-Cell Lymphoma 1.0% 79.4%
73.1–83.9%
 1.01 2025 (n=16) 56% ▸
ZIMRIXBY
RITUXIMAB-CDXX
 Chronic Lymphocytic Leukemia 1.3% 79.2%
72.9–84.3%
 1.01 2024 (n=22) 56% ▸
TRUXIMA
RITUXIMAB-ABBS
 Chronic Lymphocytic Leukemia 1.3% 79.2%
72.7–84.9%
 1.01 2024 (n=22) 56% ▸
RUXIENCE
RITUXIMAB-PVVR
 Chronic Lymphocytic Leukemia 1.3% 79.2%
73.0–84.9%
 1.01 2024 (n=22) 56% ▸
RIABNI
RITUXIMAB-ARRX
 Chronic Lymphocytic Leukemia 1.3% 79.2%
71.2–83.5%
 1.01 2024 (n=22) 56% ▸
IMFINZI
DURVALUMAB
 Non-Small Cell Lung Cancer 88.5% 78.8%
71.2–83.6%
 1.01 2020 (n=48) 56% ▸
ERBITUX
CETUXIMAB
 Colorectal Cancer 87.3% 78.1%
71.3–83.2%
 1.01 2022 (n=52) 56% ▸
ERBITUX
CETUXIMAB
 Head and Neck Cancer 87.8% 77.3%
70.3–82.8%
 1.01 2024 (n=26) 56% ▸
HERCEPTIN
TRASTUZUMAB
 Breast Cancer 85.8% 76.2%
69.0–82.4%
 1.00 2023 (n=65) 56% ▸
HERCEPTIN
TRASTUZUMAB
 Gastric Cancer 89.3% 70.5%
62.8–77.0%
 1.01 2022 (n=69) 56% ▸
Ibrance
 Breast Cancer 0.9% 49.5%
40.3–59.0%
 0.01 2023 (n=65) 56% ▸
Kisqali
 Breast Cancer 0.9% 49.5%
42.0–59.2%
 0.01 2023 (n=65) 56% ▸
Verzenio
 Breast Cancer 0.9% 49.5%
40.8–57.5%
 0.01 2023 (n=65) 56% ▸
Lynparza
 Breast Cancer 0.9% 49.5%
40.4–58.5%
 0.01 2023 (n=65) 56% ▸
Trodelvy
 Breast Cancer 0.9% 49.5%
38.8–58.4%
 0.01 2023 (n=65) 56% ▸
Enhertu
 Breast Cancer 0.9% 49.5%
42.4–58.4%
 0.01 2023 (n=65) 56% ▸
Kadcyla
 Breast Cancer 0.9% 49.5%
41.5–59.2%
 0.01 2023 (n=65) 56% ▸
Keytruda
 Non-Small Cell Lung Cancer 1.5% 43.6%
34.9–51.8%
 0.01 2020 (n=48) 56% ▸
Opdivo
 Non-Small Cell Lung Cancer 1.5% 43.6%
35.7–52.3%
 0.01 2020 (n=48) 56% ▸
Tecentriq
 Non-Small Cell Lung Cancer 1.5% 43.6%
34.5–52.0%
 0.01 2020 (n=48) 56% ▸
Imfinzi
 Non-Small Cell Lung Cancer 1.5% 43.6%
36.0–52.2%
 0.01 2020 (n=48) 56% ▸
Tagrisso
 Non-Small Cell Lung Cancer 1.5% 43.6%
36.4–51.7%
 0.01 2020 (n=48) 56% ▸
Keytruda
 Gastric Cancer 1.5% 42.2%
33.9–50.5%
 0.01 2022 (n=69) 56% ▸
Enhertu
 Gastric Cancer 1.5% 42.2%
34.3–52.7%
 0.01 2022 (n=69) 56% ▸
Keytruda
 Bladder Cancer 1.0% 42.1%
34.1–50.2%
 0.01 2020 (n=15) 56% ▸
Tecentriq
 Bladder Cancer 1.0% 42.1%
33.0–51.8%
 0.01 2020 (n=15) 56% ▸
Darzalex
 Multiple Myeloma 1.0% 41.8%
32.1–50.0%
 0.01 2023 (n=30) 56% ▸
Revlimid
 Multiple Myeloma 1.0% 41.8%
34.1–50.7%
 0.01 2023 (n=30) 56% ▸
Pomalyst
 Multiple Myeloma 1.0% 41.8%
33.9–50.9%
 0.01 2023 (n=30) 56% ▸
Velcade
 Multiple Myeloma 1.0% 41.8%
33.0–51.5%
 0.01 2023 (n=30) 56% ▸
Kyprolis
 Multiple Myeloma 1.0% 41.8%
34.1–50.0%
 0.01 2023 (n=30) 56% ▸
Keytruda
 Head and Neck Cancer 1.5% 41.4%
32.6–50.0%
 0.01 2024 (n=26) 56% ▸
Opdivo
 Head and Neck Cancer 1.5% 41.4%
30.9–50.3%
 0.01 2024 (n=26) 56% ▸
Opdivo
 Hepatocellular Carcinoma 1.5% 41.3%
32.6–48.7%
 0.01 2022 (n=15) 56% ▸
Lynparza
 Ovarian Cancer 2.1% 41.0%
32.9–48.4%
 0.01 2021 (n=40) 56% ▸
Zejula
 Ovarian Cancer 2.1% 41.0%
34.1–49.2%
 0.01 2021 (n=40) 56% ▸
Keytruda
 Melanoma 0.0% 40.8%
32.4–49.5%
 0.01 2024 (n=8) 56% ▸
Opdivo
 Melanoma 0.0% 40.8%
32.3–50.7%
 0.01 2024 (n=8) 56% ▸
Yervoy
 Melanoma 0.0% 40.8%
32.9–50.9%
 0.01 2024 (n=8) 56% ▸
Venclexta
 Acute Myeloid Leukemia 0.0% 40.8%
31.9–50.0%
 0.01 2026 (n=2) 56% ▸
Opdivo
 Renal Cell Carcinoma 0.2% 40.0%
31.7–48.4%
 0.01 2022 (n=14) 56% ▸
Calquence
 Chronic Lymphocytic Leukemia 0.5% 39.5%
30.8–48.5%
 0.01 2024 (n=22) 56% ▸
Imbruvica
 Chronic Lymphocytic Leukemia 0.5% 39.5%
32.6–48.3%
 0.01 2024 (n=22) 56% ▸
Venclexta
 Chronic Lymphocytic Leukemia 0.5% 39.5%
32.3–50.4%
 0.01 2024 (n=22) 56% ▸
Zytiga
 Prostate Cancer 0.0% 39.2%
32.0–46.6%
 0.01 2022 (n=34) 56% ▸
Xtandi
 Prostate Cancer 0.0% 39.2%
32.1–47.9%
 0.01 2022 (n=34) 56% ▸
Nubeqa
 Prostate Cancer 0.0% 39.2%
29.9–47.7%
 0.01 2022 (n=34) 56% ▸
Erleada
 Prostate Cancer 0.0% 39.2%
30.0–47.5%
 0.01 2022 (n=34) 56% ▸
AVASTIN
BEVACIZUMAB
 Breast Cancer 87.8% 5.2%
3.6–7.3%
 1.00 2023 (n=65) 56% ▸
AVASTIN
BEVACIZUMAB
 Non-Small Cell Lung Cancer 88.5% 4.2%
3.0–5.8%
 1.01 2020 (n=48) 56% ▸
AVASTIN
BEVACIZUMAB
 Colorectal Cancer 89.3% 4.0%
2.9–5.7%
 1.01 2022 (n=52) 56% ▸
AVASTIN
BEVACIZUMAB
 Gastric Cancer 89.3% 3.9%
2.8–5.4%
 1.01 2022 (n=69) 56% ▸
AVASTIN
BEVACIZUMAB
 Hepatocellular Carcinoma 91.8% 3.8%
2.7–5.2%
 1.01 2022 (n=15) 56% ▸
AVASTIN
BEVACIZUMAB
 Ovarian Cancer 87.1% 3.7%
2.6–5.0%
 1.01 2021 (n=40) 56% ▸
AVASTIN
BEVACIZUMAB
 Renal Cell Carcinoma 87.4% 3.6%
2.6–5.1%
 1.01 2022 (n=14) 56% ▸